Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization... (a pre-vaccine baseline(3). Inaddition a ...)

HOME >> MEDICINE >> TECHNOLOGY

Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules

Date:7/8/2008

a pre-vaccine baseline(3). In addition, a slight reduction in vaccine-type IPD among children aged 2-5 years old, an unvaccinated group, also was documented, suggesting a potential "indirect" effect among older children who were not immunized(3). Recent data from Germany, France and the UK highlight the impact of the vaccine in countries where it is part of the national immunization schedule," says Dr Mark van der Linden, Head of the National Reference Center for Streptococci at the Institute of Medical Microbiology, RWTH-Aachen, Germany.

The World Health Organization (WHO) recommends priority inclusion of the 7-valent pneumococcal conjugate vaccine in national childhood immunization programs worldwide due to the significant burden of pneumococcal disease and demonstrated vaccine efficac(6). Recently, the Strategic Advisory Group of Experts (SAGE) to WHO issued a preliminary recommendation that pneumococcal disease prevention be ranked as a very high priority on a global basis(6).

PREVENAR, the only licensed pneumococcal conjugate vaccine, is now available in 88 countries around the world, with more than 180 million doses distributed(1).

Pneumococcal Disease

Pneumococcal disease affects both children and adults and is a leading cause of illness and death worldwide(6). Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections, including otitis media(7). PREVENAR is the first and only pneumococcal conjugate vaccine approved to help protect infants and young children against pneumococcal disease caused by the serotypes included in the vaccine(7).

References available on request.

Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufact
'/>"/>

1

GOOD

Page: 1 2 3
Related medicine technology :

1. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
2. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
3. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
4. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
5. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
6. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis

Post Your Comments:

Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization...(a pre-vaccine baseline(3). Inaddition a ...),Health